CTNM - Contineum Therapeutics, Inc. Class A Common Stock

Stock Grade Analysis

General Rating

C+
Overall Score: 2/5
Multi-dimensional Scores
DCF: 3/5 ROE: 1/5 ROA: 1/5 D/E: 4/5 P/E: 1/5
Financial Ratios Trend

Grades Consensus

0

Strong Buy

3

Buy

1

Hold

0

Sell

0

Strong Sell

Buy

Consensus

Grade News & Updates

Date Grading Company New Grade Previous Grade Action Price When Posted News Title Publisher
2025-11-21 RBC Capital Outperform Outperform Hold $10.805 Contineum price target lowered to $22 from $25 at RBC Capit… TheFly
2025-06-18 William Blair Outperform N/A Initialise $3.65 Contineum initiated with an Outperform at William Blair TheFly
2024-08-14 RBC Capital Outperform Outperform Hold $16.4001 Contineum price target raised to $32 from $30 at RBC Capital TheFly
2024-04-30 Morgan Stanley Overweight N/A Initialise $16 Contineum initiated with an Overweight at Morgan Stanley TheFly
2024-04-30 RBC Capital Outperform N/A Initialise $16 Contineum initiated with an Outperform at RBC Capital TheFly